MLYS logo

MLYS
Mineralys Therapeutics Inc

603
Mkt Cap
$2.46B
Volume
786,960.00
52W High
$47.65
52W Low
$12.59
PE Ratio
-14.49
MLYS Fundamentals
Price
$29.85
Prev Close
$30.23
Open
$30.47
50D MA
$27.24
Beta
1.03
Avg. Volume
1.11M
EPS (Annual)
-$2.29
P/B
3.86
Rev/Employee
$0.00
$1,798.61
Loading...
Loading...

About

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
76

Frequently Asked Questions

What is Market Cap of Mineralys Therapeutics Inc?
What is the 52-week high for Mineralys Therapeutics Inc?
What is the 52-week low for Mineralys Therapeutics Inc?
What is Mineralys Therapeutics Inc stock price today?
What was Mineralys Therapeutics Inc stock price yesterday?
What is the PE ratio of Mineralys Therapeutics Inc?
What is the Price-to-Book ratio of Mineralys Therapeutics Inc?
What is the 50-day moving average of Mineralys Therapeutics Inc?
How many employees does Mineralys Therapeutics Inc have?

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available